Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment

IMPORTANCE: Patients with amnestic mild cognitive impairment (aMCI) may progress to clinical Alzheimer disease (AD), remain stable, or revert to normal. Earlier progression to AD among patients who were β-amyloid positive vs those who were β-amyloid negative has been previously observed. Current res...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:JAMA Neurol
প্রধান লেখক: Wolk, David A., Sadowsky, Carl, Safirstein, Beth, Rinne, Juha O., Duara, Ranjan, Perry, Richard, Agronin, Marc, Gamez, Jose, Shi, Jiong, Ivanoiu, Adrian, Minthon, Lennart, Walker, Zuzana, Hasselbalch, Steen, Holmes, Clive, Sabbagh, Marwan, Albert, Marilyn, Fleisher, Adam, Loughlin, Paul, Triau, Eric, Frey, Kirk, Høgh, Peter, Bozoki, Andrea, Bullock, Roger, Salmon, Eric, Farrar, Gillian, Buckley, Christopher J., Zanette, Michelle, Sherwin, Paul F., Cherubini, Andrea, Inglis, Fraser
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: American Medical Association 2018
বিষয়গুলি:
Original Investigation
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC6143120/
https://ncbi.nlm.nih.gov/pubmed/29799984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2018.0894
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি